Advances in treatment and care have improved the survival rates of patients diagnosed with cancer. Survival raises issues of treatment-related morbidity, symptom experience, and concern over the incidence of cognitive dysfunction. Methodological concerns in understanding these issues include (a) making sure one knows baseline levels of symptoms and cognitive problems in order to best determine the impact of treatment, (b) accessing the ability to use follow-up assessments of test measures appropriate to the functions of concern and the temporal issues of concern, and (c) recognizing that survivorship from cancer places an individual back on a life-span developmental track that includes both age-relevant changes in normal function and abnormal changes consequent upon other medical disorders, such as stroke or neurodegenerative disease processes.
Today's new issue of The Journal of the National Cancer Institute includes a brief communication and an editorial in this realm of clinical research. Both are available in free full-content form:
Lara H. Heflin, Beth E. Meyerowitz, Per Hall, Paul Lichtenstein, Boo Johansson, Nancy L. Pedersen, & Margaret Gatz. Cancer as a risk factor for long-term cognitive deficits and dementia. Journal of the National Cancer Institute. 2005; 97: 854–856.
Read the full Brief Communication.
Jeffrey S. Wefel & Christina A. Meyers. Cancer as a risk factor for dementia: A house built on shifting sand. Journal of the National Cancer Institute, 2005. 97: 788-789.
Read the full Editorial
Anthony H. Risser | neuroscience | neuropsychology | brain